Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. (MLSS) is described in its public disclosures as a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company’s news flow centers on its computerized drug delivery instruments, which are designed to provide painless and precise injections using its DPS Dynamic Pressure Sensing Technology® platform.
News updates commonly cover developments in Milestone Scientific’s dental segment, including expansion of direct sales programs in North America, new international registrations for the STA® Single Tooth Anesthesia System, and initiatives such as The Wand® Ambassador Program. That program uses experienced dental professionals to share real-world clinical insights and workflow considerations to support broader adoption of The Wand STA System.
In the medical segment, news items highlight the CompuFlo® technology and the CompuFlo Epidural System, including growing utilization of CompuFlo disposables, interest from hospitals and international distributors, and progress on reimbursement strategies. Milestone Scientific reports milestones such as Medicare Part B payment-rate assignments under CPT® code 0777T in several jurisdictions and early activity from commercial insurers, which it views as important for adoption in interventional pain management and spine intervention markets.
Other recurring themes in Milestone Scientific’s news include quarterly financial results, cost-management and operational transformation efforts, leadership appointments, board changes, and updates on NYSE American listing compliance matters. Investors and observers can use this news stream to follow the company’s commercial initiatives in dental and medical markets, its reimbursement and payer-access efforts, and its corporate and governance developments over time.
Milestone Scientific (NYSE: MLSS) announced that CEO Arjan Haverhals will participate in a virtual fireside chat on January 20, 2022, hosted by Maxim Group's Anthony Vendetti. This event aims to provide insights into Milestone's advanced computerized drug delivery technology, which ensures painless and precise injections. Investors can view the live webcast at 11:00 a.m. EST, with a replay available for 48 hours afterward. Milestone is focused on enhancing patient comfort and safety through its innovative DPS Dynamic Pressure Sensing Technology®.
Milestone Scientific (NYSE: MLSS) reports anticipated revenues over $2.6 million for Q4 2021, up from $2.2 million in Q4 2020, and over $10 million for FY 2021, a significant increase from $5.4 million in FY 2020. CEO Arjan Haverhals highlights growth in dental and medical divisions, with successful marketing efforts and new distributors contributing to an 85% revenue increase. The company expresses confidence in its future, citing a strong balance sheet and a substantial market opportunity in the U.S. for epidural analgesia, estimated at over $5 billion annually.
Milestone Scientific (NYSE:MLSS) recently announced that CEO Arjan Haverhals will present at the H.C. Wainwright BioConnect 2022 Conference, which occurs virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM Eastern Time for registered attendees. Milestone Scientific specializes in developing computerized drug delivery instruments aimed at providing painless injections, enhancing patient comfort and safety through innovative DPS Dynamic Pressure Sensing Technology.
Milestone Scientific (NYSE:MLSS) has expanded into the pain management market with the incorporation of the CompuFlo Epidural instrument by Dr. Harsh Govil in his practice in Statesville, NC. This decision follows a successful evaluation and aims to enhance patient safety and efficacy in pain management procedures. Arjan Haverhals, CEO, emphasized the growing traction in this sector, noting over 11 million annual epidural procedures in the U.S. Milestone aims to advance its technology beyond labor and delivery into broader applications in pain management.
Milestone Scientific (NYSE: MLSS) has announced the purchase of CompuFlo Epidural and CathCheck Verification System disposables from two prominent hospitals, enhancing its market presence. CEO Arjan Haverhals highlighted that these orders mark significant progress as both hospitals are part of large healthcare systems. The technology reportedly improves safety, efficiency, and offers economic advantages. Published studies support the technology's effectiveness, potentially reducing costs and complication rates associated with procedures.
Milestone Scientific (NYSE:MLSS) has announced a new agreement with Andau Medical to distribute its STA Single Tooth Anesthesia System in the U.S. and Canada. This partnership aims to enhance the dental experience by providing painless injections, reducing wait times, and minimizing complications. CEO Arjan Haverhals expressed optimism about the collaboration, noting Andau's strong track record in the dental market. Andau Medical’s founder, Sandi Wright, highlighted the system’s benefits for both patients and clinicians.
Milestone Scientific (NYSE:MLSS) has signed an agreement with a prestigious Northeast teaching hospital for the purchase of its CompuFlo® Epidural and CathCheck™ Verification System disposables. This follows a successful trial demonstrating the technology's safety and efficacy, enhancing accuracy in epidural procedures. The CompuFlo system is expected to reduce healthcare costs associated with morbidity and significantly decrease monitoring time for catheter placements. The company aims to expand its reach beyond labor and delivery, targeting pain management and outpatient centers.
Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Benzinga All Access event on December 16, 2021, at 10:40 A.M. Eastern Time. The presentation will recap key activities from 2021 and outline the company's sales pipeline and goals for 2022. The event will be broadcast live, and an archived recording will be accessible on Milestone's investor relations website. Milestone Scientific is known for its computerized drug delivery instruments, enhancing patient comfort and safety with innovative technologies.
Milestone Scientific (NYSE:MLSS) announced a significant step in expanding its CompuFlo Epidural instrument into the pain management market. Dr. Miguel de la Garza has started using the instrument in his practice, following approval by Surgery Partners, enhancing safety in procedures with reduced risk of complications. The overall addressable market for epidural anesthesia is around $5 billion, with pain management being twice the size of labor and delivery. CEO Arjan Haverhals emphasized the potential for capturing a significant market share with this innovative technology.
Milestone Scientific reported a 69% revenue increase to $2.1 million for Q3 2021, compared to $1.2 million in Q3 2020. This growth is driven by the reopening of dental offices and progress in their Medical segment, notably their CompuFlo Epidural instrument's deployment in Florida's Memorial Healthcare network. Despite the revenue growth, the operating loss expanded to $(2.0 million), up from $(1.5 million) in the prior year. The company has a robust financial position with about $14.5 million in cash. Milestone anticipates expanding its global presence with new distributors and aims for further growth in the medical business.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
